Clinical trial

Gefitinib Combined With Thalidomide to Treat NSCLC

NCT02387086

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Thalidomide Normalized identity: thalidomideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gefitinib Normalized identity: gefitinibView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Aspirin Normalized identity: aspirinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Gefitinib Combined With Thalidomide to Treat NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2015-05-01

PhasePHASE2 / PHASE3

Conditions

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

ThalidomideDRUG · verified · RxNorm: thalidomide

placeboDRUG

GefitinibDRUG · verified · RxNorm: gefitinib

AspirinDRUG · verified · RxNorm: aspirin

Sponsors & collaborators

Bai Junlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02387086 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.